Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 13/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 11/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 11/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19685526 | 1.00 | EGFR (0.44) | EGFRMAPK9MAPK8MAPK10MAPK14 | |
| SCHEMBL19666330 | 1.00 | EGFR (0.44) | EGFRMAPK9MAPK8MAPK10MAPK14 | |
| SCHEMBL19666332 | 1.00 | EGFR (0.44) | EGFRMAPK9MAPK8MAPK10MAPK14 | |
| SCHEMBL29717607 | 1.00 | EGFR (0.44) | EGFRMAPK9MAPK8MAPK10MAPK14 | |
| SCHEMBL19685721 | 0.95 | EGFR (0.45) | EGFRMAPK9MAPK8MAPK10MAPK14 | |
| SCHEMBL19666421 | 0.95 | EGFR (0.45) | EGFRMAPK9MAPK8MAPK10MAPK14 | |
| SCHEMBL19666417 | 0.95 | EGFR (0.45) | EGFRMAPK9MAPK8MAPK10MAPK14 | |
| SCHEMBL19666419 | 0.95 | EGFR (0.45) | EGFRMAPK9MAPK8MAPK10MAPK14 | |
| SCHEMBL19666344 | 0.94 | MAPK9 (0.44) | EGFRMAPK9MAPK8MAPK10MAPK14 | |
| SCHEMBL19666347 | 0.94 | MAPK9 (0.44) | EGFRMAPK9MAPK8MAPK10MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | claimed |
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | claimed |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2018-07-03 | — | — | US | claimed |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | claimed |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | disclosed |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| WO-2017210408-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | EGFR 4879/4885MAPK9 2986/4885MAPK8 1870/4885 |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | EGFR 4879/4885MAPK9 2986/4885MAPK8 1870/4885 |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | EGFR 4879/4885MAPK9 2986/4885MAPK8 1870/4885 |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | EGFR 4879/4885MAPK9 2986/4885MAPK8 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.